Analytik Jena Subsidiary Obtained Approval for Two New Assays
News Jul 01, 2013
AJ Roboscreen, an Analytik Jena company, recently obtained the approval for two new assays for screening of swine sera for PRRSV (porcine reproductive and respiratory syndrome virus) antibodies and for evaluation.
The new ELISA-based tests differentiate into PRRSV Type I (Europe-Type) and Type II (North America-Type).
The ELISA (Enzyme Linked Immunosorbent Assay) is an immunoassay to detect proteins in liquid samples.
"At present PRRSV causes the most important economical loss in pig industry. According to estimates, 70-80 % of all enterprises in Germany are affected by PRRSV. At least 30,000 to 35,000 tests are used for sow and piglet enterprises in Saxony per year; this corresponds to 40 % of all sows in this federal state in Germany. Resulting reproductive problems and pneumonia lead to reduced growth and vulnerability for secondary infection", said Alexander Berka, Manager of the Life Science business unit at Analytik Jena AG.
Infected animals quickly spread PRRSV within a flock via contaminated body fluids.
Losses of 25 € to 250 € per breeding sow and year are estimated. For this reason several vaccination programs are trying to raise immunity of the flocks.
"Effective containment substantially depends on early identification and quick isolation or removal of infected animals", continued Alexander Berka.
Based on a licensing agreement with the Fraunhofer Institute for Cell Therapy and Immunology, Analytik Jena developed the two new assays PRRSV DETECT-ELISA and PRRSV NA/EU TYP-ELISA.
The new ELISAs currently are a unique solution on the market for PRRSV antibody detection and differentiation for effective control and containment of this infectious and economically devastating disease.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Comments | 0 ADD COMMENT
7th International Conference on Bacteriology and Infectious Diseases
Jun 04 - Jun 05, 2018